When Regeneron Pharmaceuticals and Bayer AG signed a licensing agreement with Zydus Lifesciences to commercialise aflibercept in India, they did something telling. They chose negotiation over confrontation. That decision signals a structural shift in how global biologic innovators now view India: not as a peripheral generics market to police — but as a biologics arena to strategically engage. At the centre of this development is Aflibercept, marketed globally as Eylea, one of the most commercially successful ophthalmic biologics in the world.
This is not just a biosimilar launch. It is a pricing inflection point.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
